A surge in understanding the underlying causes of Parkinson’s disease is fueling a promising wave of potential new therapies, but significant hurdles remain in translating these advances into treatments for the approximately 10 million people worldwide living with the condition. While research has reached what experts call a “pivotal point,” funding gaps and outdated clinical trial methodologies threaten to slow progress.
For decades, treatment for Parkinson’s has largely focused on managing symptoms with levodopa, a dopamine precursor first approved over 50 years ago. Despite its effectiveness, levodopa doesn’t halt the disease’s progression, and Notice currently no approved disease-modifying therapies (DMTs). This landscape is beginning to shift, however, as researchers gain access to more sophisticated tools and a deeper understanding of the disease’s complexities.
“We know so much more about what causes Parkinson’s now, so there is a strong stream of therapeutics making their way through the pipeline,” says David Dexter, head of research at the non-profit Parkinson’s UK, in an interview with Pharmaceutical Technology. Improved testing models, including patient-derived induced pluripotent stem cells (iPSCs), are playing a crucial role in evaluating potential therapies and guiding drug development.
The Funding Gap in Parkinson’s Research
Despite the encouraging progress, securing funding for Parkinson’s research remains a major challenge. Dexter notes that previous failures in Parkinson’s drug development programs across the pharmaceutical industry have created hesitancy among investors. “Currently, funding to deliver these therapies through the development pipeline to patients’ hands is lacking – primarily due to previous failures in Parkinson’s programmes across the wider pharma landscape,” he explains.
To address this, Parkinson’s UK has established a “Virtual Biotech” scheme. This initiative provides capital to companies and institutions developing both potential DMTs and therapies aimed at managing symptoms, focusing on projects in the early stages of development – from post-target validation and preclinical studies to Phase II clinical trials. “We step in at the seed and Series A investment stages to take these projects on, derisk them and take them further down the drug development pipeline,” Dexter says.
Parkinson’s UK’s investment strategy is “target agnostic,” prioritizing projects based on scientific merit and validation. Funding has been allocated to programs across the UK, Australia, Finland, and the United States. While traditionally focused on small molecules, the organization is also exploring newer technologies like antisense oligonucleotides (ASOs), antibody therapies, and gene silencing approaches.
Addressing the Heterogeneity of Parkinson’s
Parkinson’s disease is known for its variability, presenting differently in each individual. This heterogeneity complicates drug development, as it suggests the existence of subtypes requiring tailored treatments. Identifying which patient populations will benefit most from a specific drug is a critical barrier to overcome.
Beyond motor symptoms like tremors and rigidity, Parkinson’s often involves non-motor symptoms such as anxiety, depression, insomnia, and cognitive decline, significantly impacting quality of life. Dexter emphasizes the need to address these often-overlooked aspects of the disease. “Treating non-motor symptoms…remains a major gap,” he stated.
Researchers don’t anticipate a single “magic bullet” cure for Parkinson’s. Instead, Dexter suggests that a combination of drugs and therapeutic approaches will likely be most effective. “It may be a combination of drugs bringing together multiple therapeutic approaches that will best benefit patients,” he said. He also highlighted the potential for early intervention, noting that new tests can identify individuals at risk of developing Parkinson’s up to 15 years in advance. “The earlier we can get drugs into the system, the better chance we’ve got in stopping symptomatic Parkinson’s.”
The Role of Biomarkers in Clinical Trials
Current clinical trials for Parkinson’s often rely on subjective assessments using the Unified Parkinson’s Disease Rating Scale (UPDRS), which was originally designed to evaluate symptomatic therapies, not DMTs. This can introduce variability into the data, as a patient’s symptoms can fluctuate daily. Dexter argues for a shift towards objective biomarkers – digital, blood-based, and imaging-based – to improve the accuracy and efficiency of clinical trials.
“This could also allow the wider evolution of long and costly trials to short, target engagement studies, which can aid operators determine if a drug is able to reach the brain and interact with its intended target in a safe manner,” Dexter explained. Parkinson’s UK also supports research into developing these diagnostic tools and biomarkers through a separate grant scheme.
The future of Parkinson’s research hinges on continued investment, innovative trial designs, and a deeper understanding of the disease’s complex nature. As research progresses, the hope is to move beyond symptom management and towards therapies that can slow, stop, or even prevent the progression of this debilitating condition.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the latest advancements in Parkinson’s research? Share your comments below.
